Mozistobart Biosimilar - Research Grade

Human

CD22ï؟½

5mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P20273

Blue ice

CD22 is a B-cell-restricted sialic-acid-binding receptor that regulates B-lymphocyte signaling and is frequently exploited as a target in B-cell malignancy research. We supply an unconjugated, non-therapeutic analog of mozistobart as a recombinant human IgG1 kappa antibody against CD22, designated for research use only (RUO). The low-endotoxin formulation supports in vivo experimentation, and manufacturing in scalable milligram-to-gram amounts meets the requirements of high-throughput and bulk laboratories. Researchers apply it as a B-cell-targeting control and reagent in internalization studies, in vitro screening, effector-function assays, preclinical models, and antibody-drug-conjugate development.

CAT-8015,GCR-8015,HA22,(sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks